Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial

Stamler, 2000, Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity, JAMA, 284, 311, 10.1001/jama.284.3.311 Baigent, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet, 376, 1670, 10.1016/S0140-6736(10)61350-5 Bi, 2022, Atherosclerotic cardiovascular disease risk and lipid-lowering therapy requirement in China, Front Cardiovasc Med, 9, 10.3389/fcvm.2022.839571 Li, 2021, Improvement of evaluation in Chinese patients with atherosclerotic cardiovascular disease using the very-high-risk refinement: a population-based study, Lancet Reg Health West Pac, 17 Zheng, 2017, LDL-cholesterol goal attainment under persistent lipid-lowering therapy in northeast China, Medicine, 96, 10.1097/MD.0000000000008555 2019, 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk, Atherosclerosis, 290, 140, 10.1016/j.atherosclerosis.2019.08.014 2016, Joint committee issued Chinese guideline for the management of dyslipidemia in adults. [2016 Chinese guideline for the management of dyslipidemia in adults], Zhonghua Xin Xue Guan Bing Za Zhi, 44, 833 Hirayama, 2014, Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk - primary results from the phase 2 YUKAWA study, Circ J, 78, 1073, 10.1253/circj.CJ-14-0130 Sabatine, 2015, Efficacy and safety of evolocumab in reducing lipids and cardiovascular events, N Engl J Med, 372, 1500, 10.1056/NEJMoa1500858 Robinson, 2015, Efficacy and safety of alirocumab in reducing lipids and cardiovascular events, N Engl J Med, 372, 1489, 10.1056/NEJMoa1501031 Teramoto, 2016, Efficacy and safety of alirocumab in Japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins – ODYSSEY JAPAN randomized controlled trial, Circ J, 80, 1980, 10.1253/circj.CJ-16-0387 Gragnano, 2018, Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience, J Cardiovasc Med (Hagerstown), 19, 75, 10.2459/JCM.0000000000000611 Boccara, 2017, Practical considerations for the use of subcutaneous treatment in the management of dyslipidaemia, Adv Ther, 34, 1876, 10.1007/s12325-017-0586-8 Chai, 2023, Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2), BMC Med, 21, 77, 10.1186/s12916-023-02797-8 Qi, 2023, Tafolecimab in Chinese patients with hypercholesterolemia (CREDIT-4): a randomized, double-blind, placebo-controlled phase 3 trial, JACC Asia, 3, 636, 10.1016/j.jacasi.2023.04.011 Liu, 2019, A phase 1, randomized, double-blind, single-dose, placebo-controlled safety, tolerability, and pharmacokinetic/pharmacodynamic study of evolocumab in healthy Chinese subjects>, Clin Pharmacol, 11, 145 Li, 2020, Safety, tolerability, pharmacokinetics, and pharmacodynamics of alirocumab in healthy Chinese subjects: a randomized, double-blind, placebo-controlled, ascending single-dose study, Am J Cardiovasc Drugs, 20, 489, 10.1007/s40256-020-00394-1 Cui, 2021, A potential long-acting LDL-cholesterol–lowering PCSK9 monoclonal antibody: randomized, placebo-controlled phase 1 studies, JACC Asia, 1, 411, 10.1016/j.jacasi.2021.09.002 Wu, 2017, Statins usage and target achievement of LDL-C level in Chinese patients with coronary artery disease impacted by 2013 ACC/AHA cholesterol guideline, IJC Metab Endocr, 14, 33, 10.1016/j.ijcme.2016.11.002 Bennet, 2008, Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data, Arch Intern Med, 168, 598, 10.1001/archinte.168.6.598 Kamstrup, 2009, Genetically elevated lipoprotein(a) and increased risk of myocardial infarction, JAMA, 301, 2331, 10.1001/jama.2009.801 Miksenas, 2021, Lipoprotein(a) and cardiovascular diseases, JAMA, 326, 352, 10.1001/jama.2021.3632 Bittner, 2020, Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome, J Am Coll Cardiol, 75, 133, 10.1016/j.jacc.2019.10.057 Raal, 2014, Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials, J Am Coll Cardiol, 63, 1278, 10.1016/j.jacc.2014.01.006 Tsimikas, 2020, Statin therapy increases lipoprotein(a) levels, Eur Heart J, 41, 2275, 10.1093/eurheartj/ehz310 Xie, 2022, Serum lipoprotein (a) associates with the risk of renal function damage in the CHCN-BTH study: cross-sectional and mendelian randomization analyses, Front Endocrinol (Lausanne), 13, 10.3389/fendo.2022.1023919 Kastelein, 2016, Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study, Eur Heart J, 37, 1360, 10.1093/eurheartj/ehv707 Xu, 2022, PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study, BMC Med, 20, 13, 10.1186/s12916-021-02208-w Merćep, 2022, Advantages and disadvantages of inclisiran: a small interfering ribonucleic acid molecule targeting PCSK9-A narrative review, Cardiovasc Ther, 2022, 10.1155/2022/8129513 Pang, 2021, Hyperuricemia prevalence and its association with metabolic disorders: a multicenter retrospective real-world study in China, Ann Transl Med, 9, 1550, 10.21037/atm-21-5052